# US 2016/0250217 A1 · Crystalline form of pemirolast

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250217 A1
- Document ID: US20160250217A1
- Status: Published application
- Kind: A1
- Application number: 14/880,922
- Filed: 2015-10-12
- Published: 2016-09-01
- Earliest claimed: 2009-06-16
- Assignees: RSPR Pharma AB
- Applicants: RSPR Pharma AB
- Inventors: Anett Perlberg; Martin Viertelhaus; Ulrika Rosenström; Karol Horvath
- Web page: https://patentgrep.com/patent/US20160250217A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

There is provided a hemihydrate form of the sodium salt of pemirolast.

## Claims

### Claim 1

A hemihydrate form of the sodium salt of pemirolast.

### Claim 2 (depends on 1)

A compound as claimed in claim 1, which contains between about 0.3 and about 0.7 moles of water per mole of pemirolast.

### Claim 3 (depends on 1, 2)

A compound as claimed in claim 1 or claim 2, which is substantially crystalline.

### Claim 4

A compound as claimed in any one of the preceding claims which is substantially crystallographically pure.

### Claim 5

A compound as claimed in any one of the preceding claims characterised by a powder X-ray diffraction pattern comprising a characteristic crystalline peak with a 2-Theta value (in degrees) of around 26.6.

### Claim 6 (depends on 5)

A compound as claimed in claim 5 characterised by a powder X-ray diffraction pattern comprising a further strong crystalline peak with a 2-Theta value of around 25.3.

### Claim 7 (depends on 5, 6)

A compound as claimed in claim 5 or claim 6 characterised by a powder X-ray diffraction pattern comprising further strong crystalline peaks with 2-Theta values of around 13.0, 15.3, 18.2 and/or 28.4.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A process for the preparation of a compound as claimed in any one of claims 1 to 7, which comprises crystallisation from a solvent.

### Claim 9 (depends on 8)

A process as claimed in claim 8 which further comprises reacting pemirolast with a sodium-containing base prior to the crystallisation.

### Claim 10 (depends on 9)

A process as claimed in claim 9 wherein the base is sodium hydroxide or a sodium alkoxide.

### Claim 11 (depends on 8, 9, 10)

A process as claimed in any one of claims 8 to 10 wherein the solvent comprises a lower alkyl alcohol.

### Claim 12 (depends on 11)

A process as claimed in claim 11, wherein the solvent is methanol or ethanol.

### Claim 13 (depends on 8, 9, 10, 11, 12)

A process as claimed in any one of claims 8 to 12, wherein the crystallisation comprises partial dissolution of pemirolast sodium in the solvent, in the presence of no more than about 10% (w/w, as a proportion of the solvent) of water.

### Claim 14 (depends on 13)

A process as claimed in claim 13, which is carried out at a temperature of less than about 70° C.

### Claim 15 (depends on 8, 9, 10, 11, 12)

A process as claimed in any one of claims 8 to 12, wherein the crystallisation comprises partial dissolution of pemirolast sodium in an aqueous solvent at about 72° C. or above.

### Claim 16 (depends on 15)

A process as claimed in claim 15, which further comprises filtration at about 72° C. or above to isolate the compound.

### Claim 17 (depends on 8, 9, 10, 11, 12)

A process as claimed in any one of claims 8 to 12, wherein the crystallisation comprises dissolution of pemirolast sodium in an aqueous solvent followed by addition of an excess of antisolvent.

### Claim 18 (depends on 17)

A process as claimed in claim 17, wherein the antisolvent comprises ethanol.

### Claim 19 (depends on 17, 18)

A process as claimed in claim 17 or claim 18 wherein the antisolvent is added at around the boiling point of the solvent until precipitation takes place, and the resultant is cooled to about room temperature.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7)

A process for the preparation of a compound as claimed in any one of claims 1 to 7, which comprises dehydration of a higher hydrate of pemirolast sodium.

### Claim 21 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A compound obtainable by a process according to any one of claims 8 to 20.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

A compound as defined in any one of claim 1 to 7 or 21 for use as a pharmaceutical.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

A pharmaceutical formulation including a compound as claimed in any one of claim 1 to 7 or 21 in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

A compound as defined in any one of claim 1 to 7 or 21 for use in the treatment of an inflammatory disorder.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

The use of a compound as defined in any one of claim 1 to 7 or 21 for the manufacture of a medicament for the treatment of an inflammatory disorder.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

A method of treatment of an inflammatory disorder, which method comprises the administration of a compound as defined in any one of claim 1 to 7 or 21 to a patient in need of such treatment.

### Claim 27 (depends on 24, 25, 26)

A compound as claimed in claim 24, a use as claimed in claim 25, or a method as claimed in claim 26, wherein the disorder is atherosclerosis or an associated cardiovascular disorder.

### Claim 28 (depends on 27)

A compound, use or method as claimed in claim 27, wherein the disorder is atherosclerosis.

### Claim 29 (depends on 27)

A compound, use or method as claimed in claim 27, wherein the cardiovascular disorder associated with atherosclerosis is selected from an aortic aneurysm, arteriosclerosis, peripheral arterial occlusive disease, a coronary artery disease, a coronary disease, plaque rupture and/or instability, atheroma rupture and/or instability, a vascular disease, an arterial disease, an ischaemic disease, ischaemia and stroke.

### Claim 30 (depends on 29)

A compound, use or method as claimed in claim 29, wherein the coronary artery disease is selected from angina pectoris, myocardial infarction and heart attack; the coronary disease is selected from a cardiac disease and a heart disease; the stroke is selected from cerebro-vascular accident and transient ischaemic attack; and/or the disorder is plaque rupture and/or instability, or atheroma rupture and/or instability.

### Claim 31 (depends on 29)

A compound, use or method as claimed in claim 29, wherein the disorder is an aortic aneurysm.

### Claim 32 (depends on 27, 28, 29, 30, 31)

A compound, use or method as claimed in any one of claims 27 to 31, wherein the patient has an acute coronary syndrome.

### Claim 33 (depends on 24, 25, 26)

A compound as claimed in claim 24, a use as claimed in claim 25, or a method as claimed in claim 26, wherein the disorder is systemic low grade inflammation.

### Claim 34 (depends on 24, 25, 26)

A compound as claimed in claim 24, a use as claimed in claim 25, or a method as claimed in claim 26, wherein the disorder is selected from metabolic syndrome, obesity, diabetes mellitus and/or a diabetic vascular complication.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

A combination product comprising:
(a) a compound as defined in any one of claim 1 to 7 or 21; and
(b) one or more active ingredient that is useful in the treatment of an inflammatory disorder, or a pharmaceutically-acceptable salt or solvate thereof.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 21, 35)

A combination product as claimed in claim 35, which comprises a pharmaceutical formulation including a compound as defined in any one of claim 1 to 7 or 21; an active ingredient that is useful in the treatment of an inflammatory disorder, or a pharmaceutically-acceptable salt or solvate thereof; and a pharmaceutically-acceptable adjuvant, diluent or carrier.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 21, 35)

A combination product as claimed in claim 35, which comprises a kit of parts comprising components:
(A) a pharmaceutical formulation including a compound as defined in any one of claim 1 to 7 or 21, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and
(B) a pharmaceutical formulation including an active ingredient that is useful in the treatment of an inflammatory disorder, or a pharmaceutically-acceptable salt or solvate thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,
which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.

### Claim 38 (depends on 35, 36, 37)

A combination product as claimed in any one of claims 35 to 37, wherein the active ingredient that is useful in the treatment of an inflammatory disorder is a thromboxane A2 antagonist, a P2Y12 antagonist, a PPARγ agonist, a compound that inhibits the formation and/or action of angiotensin II, a platelet aggregation inhibiting drug or a statin.

### Claim 39 (depends on 38)

A combination product as claimed in claim 38, wherein the active ingredient is a statin.

### Claim 40 (depends on 39)

A combination product as claimed in claim 39, wherein the active ingredient is atorvastatin or rosuvastatin.

### Claim 41 (depends on 38)

A combination product as claimed in claim 38, wherein the active ingredient is aspirin/acetylsalicylic acid, egualen, ozagrel, picotamide, terutroban, seratrodast, ramatroban, prasugrel, ticagrelor, clopidogrel, rivoglitazone, naveglitazar, balaglitazone, rosiglitazone, pioglitazone, captopril, perindopril, ramipril, candesartan, losartan, valsartan or aliskiren.
